Physician profile
Martin Schear
NPI 1801885355
$28,303.71
in general payments reported to CMS, 2019-2025
69 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $9,126 · 2020: $1,836 · 2021: $6,470 · 2022: $2,450 · 2023: $2,372 · 2024: $4,240 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,863 · Travel and Lodging: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,862.50 |
| Travel and Lodging | $1,559.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $6,076.45 | 2019-2025 | |
| Life Technologies Corporation | $4,250.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $4,114.46 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,547.11 | 2019-2025 | Bexsero, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $1,654.23 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $1,474.37 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Seqirus USA INC | $1,176.02 | 2019 | |
| Novo Nordisk INC | $677.52 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $565.90 | 2021-2025 | |
| Amarin Pharma, INC. | $497.53 | 2019-2022 | |
| Astrazeneca Uk Limited | $470.07 | 2022 | |
| Astellas Pharma US INC | $404.16 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.64 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Dexcom, INC. | $327.70 | 2021-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $258.32 | 2019-2023 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $230.76 | 2020-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $229.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $195.59 | 2019-2021 | |
| Lilly USA, LLC | $192.57 | 2020-2024 | Emgality, Reyvow, Jardiance |
| Cequr Corporation | $192.45 | 2024-2025 | Cequr Simplicity |
| Amgen INC. | $166.47 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.19 | 2019-2023 | Cycloset |
| Allergan, INC. | $157.00 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $155.18 | 2022-2025 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $143.98 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $131.85 | 2019-2025 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $130.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $124.60 | 2020-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $101.39 | 2019-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.29 | 2021-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $100.49 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $86.16 | 2024-2025 | |
| Mylan Specialty L.P. | $84.37 | 2023-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $73.40 | 2023 | Rexulti, Abilify Maintena |
| Tempus Ai, INC | $61.15 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $49.06 | 2019-2024 | Eliquis |
| Sk Life Science, INC. | $44.21 | 2021-2022 | |
| Medtronic, INC. | $43.20 | 2022-2025 | Venaseal |
| Sunovion Pharmaceuticals INC. | $42.25 | 2019-2021 | |
| Shield Therapeutics INC | $41.08 | 2023-2024 | Accrufer |
| Phathom Pharmaceuticals, INC. | $40.74 | 2024-2025 | Voquezna |
| Mannkind Corporation | $38.22 | 2025 | |
| Genentech, INC. | $38.00 | 2019 | |
| Neurelis, INC. | $37.74 | 2023 | Valtoco |
| Lifescan, INC. | $32.84 | 2020 | |
| Sanofi-Aventis U.S. LLC | $29.28 | 2019 | |
| Insulet Corporation | $25.65 | 2021 | |
| Hikma Pharmaceuticals USA | $25.19 | 2019-2021 | |
| Axsome Therapeutics, INC. | $23.57 | 2025 | Symbravo |
| Pulmonx Corporation | $18.52 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Mycovia Pharmaceuticals, INC. | $17.20 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $17.00 | 2025 | Rhythm Express |
| Covis Pharma Gmbh | $14.89 | 2019 | |
| Opko Pharmaceuticals, LLC | $14.84 | 2019 | |
| Athena Bioscience, LLC | $14.54 | 2022 | |
| Alkermes, INC. | $12.75 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.71 | 2021 | |
| Gilead Sciences, INC. | $12.24 | 2020 | |
| Supernus Pharmaceuticals, INC. | $11.13 | 2021 |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,875.84 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Schear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.